When to get funding for startup?

Funding is not a badge of seriousness; it’s a tool. The right time to raise is when money will predictably buy speed on a specific bottleneck (building, selling, regulatory, hiring) and you can show evidence that the next milestone is achievable.

If you’re a technical/medical/scientific founder, the most common mistake is raising too early (giving away too much equity before you’ve reduced risk) or too late (running out of runway and negotiating from weakness). The goal is to raise when you have enough proof to get good terms, but still early enough that capital meaningfully accelerates you.

The core rule: raise when capital converts to milestones

Investors fund risk reduction. Your job is to show which risks are already reduced and which ones funding will reduce next.

A practical way to decide is to map your startup to four risks:

• Problem risk: Does a painful problem exist, and do people agree it’s worth solving?
• Solution risk: Does your approach work well enough to be valuable?
• Market risk: Can you reach buyers/users at a reasonable cost and convert them?
• Execution risk: Can your team deliver reliably (product, sales, operations)?

You should raise when you can credibly say: “We’ve reduced X and Y risks; with $Z we will reduce the next risk by hitting milestone M by date D.” That’s what makes a round feel “inevitable” rather than speculative.

Milestones that signal you’re ready (by stage)

Funding stages are just labels for how much risk you’ve removed. Here are concrete readiness signals that apply across most startups.

Bootstrapping / pre-funding (often the best default)

Stay unfunded when you can still make meaningful progress with time, focus, and small costs. Typical milestones before raising:

• Clear ICP (Ideal Customer Profile): a specific “who” (e.g., outpatient clinics with 5–20 providers; mid-size manufacturing QA teams).
• 10–30 customer discovery interviews with consistent pain patterns and current workarounds.
• A narrow wedge: one use case you can win first (not “the platform”).
• Prototype or demo that proves the core workflow, even if it’s ugly.

If you can reach these without funding, you’ll raise later at a higher valuation (meaning you give up less ownership).

Pre-seed (prove demand + de-risk the first build)

Pre-seed is for turning “we think” into “we know.” Strong signals:

• Evidence of pull: people ask for pilots, intros, or “when can we use it?”
• LOIs (Letters of Intent) or paid design partners. An LOI is not revenue, but it shows seriousness if it includes scope, timeline, and pricing assumptions.
• Founder-market fit: your domain credibility clearly helps you access customers and build the right thing.

Raise pre-seed when money will buy speed to a specific next proof point: MVP completion, first pilots, or a measurable technical validation.

Seed (prove repeatability)

Seed is for showing you can do the same thing more than once. Signals include:

• Working MVP used by real users (not just friends).
• Early revenue or a clear path to it (for enterprise, signed pilots can count if they’re paid and time-bound).
• Retention or usage that suggests value (e.g., weekly active usage in a workflow product; repeat orders in a B2B service).
• A repeatable go-to-market motion: you can describe how leads are generated, how sales closes, and typical cycle time.

If you can’t explain why customer #5 will be easier than customer #1, you’re usually early for seed.

Series A and beyond (scale what works)

Later rounds are for scaling a proven machine: hiring sales, expanding channels, increasing marketing spend, and building adjacent products. Readiness looks like:

• Predictable unit economics: you roughly know CAC and LTV. CAC is Customer Acquisition Cost; LTV is Lifetime Value.
• Stable retention and clear expansion paths (upsell, cross-sell, usage-based growth).
• Operational maturity: onboarding, support, and delivery don’t break as volume grows.

Three “raise now” triggers (and three “don’t raise yet” warnings)

Raise now if…

• You have a bottleneck money can remove: e.g., hiring a key engineer, paying for a clinical pilot setup, accelerating sales outreach, or building a compliance-ready version.
• You can define the next milestone in one sentence: “With $500k we will ship V1, onboard 10 paying customers, and reach $20k MRR within 9 months.” (Numbers vary; the point is specificity.)
• Your leverage is improving: inbound interest, multiple investor conversations, or customer traction that creates competition for the round.

Don’t raise yet if…

• You can’t explain who pays and why. “Hospitals” is not a customer; a specific buyer and budget line is.
• Your story depends on “once we build it, they’ll come.” That’s solution-first risk. Do more discovery and pre-sales.
• You’re raising to feel safe rather than to hit a milestone. Funding doesn’t remove uncertainty; it buys attempts.

How much to raise: runway, dilution, and the milestone budget

A clean way to size a round is: milestone cost + buffer.

• Milestone cost: the minimum spend to reach the next fundable proof point (e.g., MVP + 10 pilots; or $X MRR; or a validated technical benchmark).
• Buffer: typically 3–6 months of extra runway for surprises and fundraising time.

Runway is how long you can operate before cash hits zero. Many founders aim for roughly 12–18 months of runway after closing a round, because fundraising itself can take months and you want time to execute before you’re back on the road.

Also watch dilution (the ownership you give up). Early rounds often trade meaningful equity for speed. If you can delay fundraising until you have stronger proof, you often give up less for the same cash. But delaying too long can force a “down round” (raising at a lower valuation than before) or desperate terms.

Choosing the right funding type (not all money is equal)

“Funding” can mean different instruments with different tradeoffs:

• Bootstrapping: slowest but highest control. Great when you can sell early and build incrementally.
• Angel / pre-seed equity: flexible, relationship-driven, good for early risk reduction.
• Convertible note / SAFE: common early-stage instruments that delay setting a valuation. A SAFE is a Simple Agreement for Future Equity.
• Venture capital (VC): best when you’re building a large market business that benefits from speed and can return a large outcome. VC expects growth and a path to a big exit.
• Revenue-based or debt: can work once you have predictable revenue; less dilution but requires repayment discipline.

Match the money to the business. If your path requires long validation cycles (common in scientific/medical contexts), you may need investors who understand that timeline—or structure milestones so you can show progress without overpromising.

What to do next

1. Write your “next milestone sentence”: “With $X we will achieve Y by date Z.” If you can’t write it, you’re not ready to raise.
2. Build a milestone budget: list the 3–5 biggest cost drivers (people, compute, pilots, compliance, sales) and estimate monthly burn to reach that milestone.
3. Run 15 targeted customer conversations with your ICP and ask for a concrete commitment (paid pilot, LOI with scope, or intro to the budget owner).
4. Pressure-test your round readiness using /roast or compare positioning with /Competitor_study.
5. Model dilution and runway before you talk to investors using /finances so you know what “good terms” look like for you.